Nitric oxide (NO) is a pleiotropic signaling molecule, and may be a contributing factor to the hypoxia encountered in a variety of solid tumors. Previously we reported that increased NOS expression resulted in a concomitant increase in expression of the glucose-regulated protein 78 (GRP78) in human embryonic kidney 293 cells. In the present study, we found that GRP78 was expressed on the cell membrane after nitric oxide induction. In order to isolate membrane-bound GRP78, we have designed a novel scFv library screening method, based on alternative screening with recombinant protein and cell surface-expressed antigen. After first routine screen using GRP78 protein, we used NO-induced cell surface GRP78 as a bait to subtract the none-membrane binding phages. We have successful isolated a panel of scFv specific for GRP78. Treatment of cells with one of the scFv (scFv-GRP78-H19) attenuated the GRP78-mediated protection against thapsigargin, a selective ER Ca 2+ -ATPase inhibitor. Furthermore, it synergized with ionomycin (IM) to promote apoptosis in prostate cancer cells and inhibited the glucose-deprivationmediated etoposide resistance in human colon and prostate cancer. The work presented here has highlighted the possibility that anti-GRP78 antibodies have the potential to be used therapeutically for the treatment of cancer.
Introduction
In recent years, monoclonal antibodies (MAbs) have become accepted tools for the detection and treatment of cancer [1, 2] . Unmodified antibodies have been approved for the treatment of a variety of cancers including non-Hodgkins lymphoma (Rituximab), breast cancer (Trustuzumab), acute myeloid leukaemia (Gemtuzumab), B-cell chronic lymphocytic leukaemia (Alemtuzumab) and colorectal cancer (Cetuximab, and Bevacizumab). Although the targets for therapeutic antibodies are diverse, they share several important characteristics in that they are expressed on tumor cells but not on healthy tissue, and are surface exposed to be easily targeted by the therapeutic antibody.
The mechanism by which antibodies bring about tumor cell death are often complex, but can include recruitment of effector elements (such as complement, or cell-mediated killing processes), or by interacting with receptor-ligand signaling pathways that may result in apoptosis. The traditional method for raising tumor-specific antibodies has been to immunize mice with tumor cells and then to screen for specific MAbs. However, direct selecting the tumor cell surface antigen remains a very difficult task, especially by using tumor cells directly screening naï ve phage display libraries due to non-specific cell surface binding of phages, considerable time-consuming proteomic analysis follow-up work and selection of dominant clones [3, 4] .
We have been examining the biological consequences arising from the expression of nitric oxide synthase (NOS) activity in a cell [5] . NOS activity has been reported in both cancer cell lines and in tumor biopsies, and while high concentrations of NO appear to have anti-tumor properties, lower concentrations are thought to promote tumor growth and neovascularisation [6] . Exposure of a cell to NO has been shown to alter the expression of the cellular transcriptome. In order to study this process systematically, we have developed two regulated cell expression systems where inducible NOS (iNOS) is placed under the control of tetracycline and ecdysoneregulated promoters. Following transfection, the resulting cell lines can generate NO in a dose-and time-dependent manner at concentrations found in biopsies of human tumors [7, 8] . Microarray analysis for both inducible cell lines has shown that NO-mediated regulation can result in the protection of the cells from environmental stress. For example, up-regulation of the DNA-dependent protein-kinase catalytic subunit (DNA-PKcs) is involved in protecting cells from DNA damage [7] while up-regulation of GRP78 [9] is involved in protection against endoplasmic reticulum (ER)-stress. These findings have led us to suggest that exposure of cells to sub-lethal "priming" with NO results in not only protection against higher concentrations of NO but also protection from other cytotoxic anti-tumor agents. Consequently, NO-regulated genes that are also up-regulated in tumor cells may be good targets for anti-tumor therapy. To test this approach, we decided to target GRP78, as it can be found on the surface of tumor cells [10] [11] [12] and provide ER stressmediated cytoprotection in cancer cells [13] .
Materials and Methods

Cell culture and immunocytohistochmistry
EcR293 clone-11 subclone-1 cells have been described previously [9] . Cancer cell lines, PC-3(human prostate cancer) and HT-29(human colon cancer) were obtained from the European Collections of Cell Culture. The cells were stained either with an affinity-purified goat polyclonal antibody against the N-terminal peptide of GRP78 (Santa Cruz Biotechnology, CA) or with scFv-GRP78-H19. For staining with the anti-peptide antibody, pre-immune goat sera was used as a negative control. For staining with the scFv antibody, slides staining without first antibody were used as a negative control. A standard Vecta-stain "ABC kit" (Vector Laboratories, UK) was used with indirect avidin-biotin horseradish peroxidase staining. Indirect immunofluorescence was used to visualize GRP78 protein in the cells. Cells were grown on cover-slips in 6-well plates, washed with PBS, and fixed with PBS/2% formaldehyde for 30 min at room temperature. After incubation, the cells were stained with anti-GRP78 antibody (Santa Cruz Biotechnology diluted 1:200) or with scFv-GRP78-H19 diluted (1:200) in PBS. In the case of scFv-GRP78-H19, the second antibody was targeted against the cmyc-tag (mouse MAb 9E10, Cambridge Research Biochemicals, Wilmington, DE) in 1:1000 dilutions. Cells were incubated for 45 min at 37°C with FITC-conjugated affinity-purified goat anti-goat IgG or with anti-mouse IgG-Texas-red conjugate diluted 1:100. In some cases, a second antibody against the c-myc-tag fluro555 conjugate (Upstate Ltd, Dundee, UK) was also used (diluted 1:200). After washing three times in PBS, images were captured on a confocal microscope (Leica TCS SP, Germany).
Selection of cell surface targeting anti-GRP78
-specific scFv by cell surface subtractive screen GRP78 protein was purified as described previously [14] and was used to coat immunotubes for scFv panning experiments and later subtractive screening.
The Tomlinson naï ve human scFv libraries I + J (15, comprising 10 8 different scFv fragments, MRC Geneservice, UK) were screened using the protocol recommended by the MRC Geneservice, UK. In the first round of panning, 1 x 10 12 phage were added to immuno-tubes coated with 10 g ml -1 recombinant murine GRP78. Phage repertoires recovered from this step were used in a second round of panning using the whole cell surface as bait. EcR293 clone-11 subclone-1 cells were grown as an attached monolayer in T25 flasks until almost confluent and induced to generate NO by treatment with 10 M muristerone A for 16 h, resulting in a 3-4 fold increase in GRP78 protein [9] . 2 x 10 6 cells were washed with PBS, and fixed with 4% paraformaldehyde (Sigma, UK) for 10 min at room temperature. The fixed cells were washed with PBS and blocked with 2% MPBS (PBS supplemented with milk powder to a final concentration of 2%) for 2h at room temperature. Meanwhile, the phage repertoires recovered from the first-round panning against GRP78 protein were separately incubated with 50:50 volume of 4%MPBS and DMEM medium(Invitrogen, UK). After 2% MPBS blocking, the cells were incubated with preblocked phage repertoires in 50:50 volumes of 4%MPBS and DMEM medium for 2h at room temperature to isolate anti-GRP78 antibodies that recognised surface-exposed epitopes. After incubation, the cells washed rapidly 10 times with PBS at room temperature. Phage adhering strongly to the cell surface were eluted following treatment with trypsin (1 mg ml -1 in 1 mM CaCl 2 , 50 mM Tris-HCL, pH 7.4), and were used to re-infect E. coli with help phage TG-1. Two more rounds of panning were carried out against recombinant GRP78 (10 g ml -1 ) to isolate specific anti-GRP78 scFv. After the fourth round of panning, a panel of 200 phage was picked and the encoded scFv antibody screened using an enzyme-linked immunosorbent assay (ELISA) against recombinant GRP78 protein (as described in the MRC protocol). ELISA-positive phage were used to re-infect E. coli HB2151 (a non-suppressor strain), and the resulting soluble anti-GRP78 scFv purified using Ni-TED spin column chromatography according the manufacturer"s recommended conditions (Ni-TED, Active Motif Europe, Rixensart, Belgium).
Surface Plasmon Resonance
Surface Plasmon Resonance studies on the binding of scFv-GRP78-H19 to GRP78 were carried out on a Biacore 3000, essentially following the manufacturer"s recommended conditions (Biacore, Uppsala, Sweden). Briefly, the GRP78 protein and control protein BSA were immobilized on CM5 chips(Biacore) with surface densities of 200 resonance units(RU) using amine-coupling kit(BIAcore). Antibody injections were performed in a concentration range of 9.37-74nM. Assoication and dissociation data from all concentrations were fit globally using Biaeval 4.1 with 1:1 Langmuir binding model.
Cell Surface analysis of GRP78 by flow cytometry
Cells were fixed with 2% paraformaldehyde for 30 mins and preincubated with 1% horse serum for further 1h. The cells were stained with anti-GRP78 antibody, scFv-GRP78-H19 (1:00 dilution) overnight with slow rotation. After washed with PBS, c-myc-tag (mouse MAb 9E10) in 1:500 dilutions were added the cells for 1h. After washed with PBS, cells were staining with goat F(ab") 2 fragment anti-mouse IgG-FITC (Beckman Coulter, UK). In negative controls, the first antibody scFv-GRP78-H19 was omitted in the staining procedure. At lease 5x10 3 cells were analyzed on a FACSCalibur (BD Biosciences. UK) using Cellquest and FlowJo software.
Cell growth assay and cytoprotection assay
Thapsigargin (TG) and cell viability experiments were carried out essentially as described previously [9] . Briefly, EcR293 clone-11 subclone-1 cells were treated with muristerone A (10 M) for 16 h and were subsequently exposed to TG (37 nM) with or without antibody. Cell viability was determined after 48 h using an LDH cytotoxicity detection kit (Roche, Lewes, UK). To detect apoptosis, PC-3 cells or HT-29 cells were exposed to IM (100 nM) or etoposide (10µg/ml) in the presence of scFv-GRP78-H19 (83 nM) for 48-76 h. Control treatments were carried out either using unrelated antibody scFv-A20 or heat-inactive antibody (100 0 C, 20 mins). For etoposide treatment, 2-Deoxyglucose (2DG, 20mM) was added into culture medium for 16h before adding etoposide. Detection of nuclear chromatin condensation was carried out with the Hoechst dye H33342 (10 g ml -1 ) for 15 min, and nuclei were visualized using a Leica DMIRB inverted fluorescence microscope. A minimum of 200 cells were counted in each sample and condensed or fragmented nuclei were expressed as a percentage of the total number of nuclei.
Detection of Caspase-3/7 activity
Dual caspase-3/7 activity was determined with an Apo-ONE caspase-3-7 assay kit (Promega, UK) using the manufacturer"s conditions. PC-3 cells (1x10 5 cells ml -1 ) were grown in 6-well plates and exposed to IM (100 nM) alone or in the presence of scFv-GRP78-H19 (83 nM) or the control antibody scFv-A20 for 76 h. Caspase activity was measured as a relative fluorescence unit (RFU) using a SpectraMax Plus spectrophotometer (485 nm excitation, 527nm emission). Western blot analysis was carried out essentially as previously described [9] . GRP78 antibody was from BD Bioscience, Oxford, UK.
Sequencing and Antibody epitope mapping
Qiagen DNA purification kit was used to isolate phagemids DNAs. The sequence primers for V H was 5"-CGACCCGCCACCGCCGCTG and for V k was 5"-CTATGCGGCCCCATTCA. For the antibody epitope mapping, human GRP78 N-terminal 20 amino acid synthetic peptides (SC-1050P, Santz Cruz, CA, USA) and C-terminal 20 amino acid synthetic peptides (SC-1051P, Santz Cruz, CA, USA) were spotted on nitrocellulose membrane and probed with scFv antibodies. The second antibody was targeted against the c-myctag mouse MAb 9E10, in 1:1000 dilution and a standard Vecta-stain "ABC kit" was used with indirect avidin-biotin horseradish peroxidase staining. The brown positive staining were scanned and analyzed with Scan analysis (Cambridge, UK) program. 
Results
GRP78 is expressed on the cell membrane after nitric oxide induction
We have shown previously that NO can mediate an increase in GRP78 protein in an ecdysone-inducible human embryonic kidney (EcR293) cell line [9] . Treatment of EcR293 clone-11 subclone-1 cells with 10 M muristerone A for 16 h resulted in a 3-to 4-fold increase in GRP78 [9] . Fluorescence immunohistochemistry was carried out on these cells using an anti-GRP78 N-terminal antibody and FITCconjugated affinity-purified goat secondary antibody. A strong surface staining of GRP78 protein was observed in NO-generating cells (Fig.  1B) in comparison with un-induced cells (Fig.1A) . There was no specific staining in the control cells in which the pre-immune serum was used (Fig. 1C, un-induced and Fig1D, induced) .
Isolation of anti-membrane-bound GRP78 scFVs using subtractive-screening in a phage display library
To isolate antibodies that recognized surfaceexposed GRP78, we decided to use this cell line to subtract the non-cell surface binding GRP78 from human native phage display libraries ( Fig.2A) . Two human scFv-phage display libraries [15] , (Tomlinson I and J human single fold scFv libraries) were screened initially against recombinant GRP78 protein [14] . The resulting GRP78-specific phage were pooled and applied to a monolayer of EcR293 clone-11 subclone-1 cells that had been treated with 10 M muristerone A to express GRP78 on the cell surface [9] . After this whole cell selection step ( Fig.2A) , the cells washed rapidly 10 times with PBS at room temperature. Phage adhering strongly to the cell surface was eluted following treatment with trypsin. Around 3x10 4 phage were recovered from 1x 10 11 phage repertoires. After this subtractive screen to separate the phages binding to the cell surface to non-cell surface phage binder, two further rounds of screening were carried out against recombinant GRP78 protein. A panel of 200 phage were picked and the encoded scFv antibody screened using an enzyme-linked immunosorbent assay (ELISA) against recombinant GRP78 protein. 19 positive phage have been identified by Elisa assay. Total three different unique clones have been identified by sequencing. One of the antibodies isolated by this procedure, scFv-GRP78-H19, was selected for further study and was shown by immunohistochemistry to detect surface-located GRP78. The antibody showed a strong signal for cell surface GRP78 in the NO-generating cells (Fig. 2C ) and a relatively low cytoplasmic staining in un-induced cells (Fig.2B) . No specific staining was detected in control samples in which the primary antibody was omitted (Fig. 2D) . ScFv-GRP78-H19 was also able to detect GRP78 in western blots of whole cell extracts while it did not cross-react with the negative control bovine serum albumin, BSA (Fig. 2E) . Purified soluble scFv-GRP78-H19 has a molecular weight of around 30 kDa (Fig. 2F) . Flow cytometric analysis using the antibody revealed a strong cell surface-located GRP78 fluorescence signal in NO-generating cell (Fig. 2G , Muristerone A treatment), in comparison with uninduced cells. There was little fluorescence present in negative control. Fig.4 . ScFv-GRP78-H19 antibody epitope mapping. Four different proteins or peptides (200 µg/ml) were spotted on a nitrocellulose filter and probed with ScFV-GRP78-H19 antibody. The signal intensity of GRP78 protein spot was used as internal control as 1. Only GRP78 N20 peptide (SC-1050P, which cover N-terminal 10-60 amino acids epitope of GRP78) has strong immunodetection signal (80%) in comparison with GRP78 protein (n=3).
The deduced amino acid sequences of the variable heavy-chain and the light-chain regions from the three unique selected GRP78-specific scFvs are shown on Fig3A. They all comprise a V H3 heavy chain and a V L1 light chain ( Fig. 3A ; data generated using the DNAPLOT and VBASE programs from the MRC Protein Engineering Centre; www.mrc-cpe.cam.ac.uk). Furthermore, scFv-GRP78-H19 was shown to bind to GRP78 in surface plasmon resonance (SPR) experiments with the kinetic constants for dissociation (Kd) at 17.8nM (n=3, BIAevaluation 4.1, Fig.3B ). To map the antibody epitope, we have taken advantaged of the immunofluorescence staining pattern of the scFv-GRP78-H19 being very similar as that of anti-human GRP78 N-terminal 20 amino acid synthetic peptide antibody (SC-1050, Santz Cruz, CA, USA)(Xu et al., unpublished data). The immuno-reaction of the antibody to N20 terminal peptides(SC-1050P,range from 10-60 amino acids of human GRP78) have similar strong as GRP78 protein, while no immuno-reaction with C00H-terminal GRP78 peptide(SC-1051P) and BSA(Fig4), indicating the antibody epitope located on the NH(2)-terminal domain of GRP78 at 10-60 amino acids (Fig.4) .
ScFv-GRP78-H19 and GRP78-mediated cytoprotection
We have shown previously that NO generation in a cell increased the concentration of GRP78 and resulted in cytoprotection against thapsigargin (TG), a selective ER Ca 2+ -ATPase inhibitor [9] . To investigate whether treatment with an anti-GRP78 antibody could reverse this protection, EcR293 clone-11 subclone-1 cells were treated with 10 M muristerone to induce NO production and increase the concentration of GRP78. After 16 h, cells were exposed to TG (37 nM) in the presence of either scFv-GRP78-H19 (83 nM) or with the same concentration of a non-GRP78 cross-reactive control antibody (scFv-A20, EMBL Access number AM939369). Treatment with scFv-GRP78-H19 (Fig. 5A ) abolished completely the NO-mediated cytoprotection at 48 h. The negative control antibody scFv-A20 had no apparent effect on cell survival (Fig. 5A ) nor did treatment with 83 nM of a commercially available anti-GRP78 MAb (BD Transduction Labs, Cat 610979).
GRP78 has been shown previously to provide cytoprotection against apoptosis in the prostate cancer cell line PC-3 mediated by the calcium ionophore ionomycin (IM) [16] . To extend our protection studies, PC-3 cells were treated with IM and scFv-GRP78-H19 (83 nM) (Fig.5B) . Although treatment with scFv-GRP78-H19 or IM alone produced a low but significant increase in the number of fragmented nuclei and nuclei with DNA strand breaks (judged by Hoechst 33342 staining), a combination of IM and antibody resulted in a significant increase in apoptotic nuclei. The combination of scFv-GRP78-H19 and IM resulted in significantly more apoptotic cell death (38%) than treatment with scFv-GRP78-H19 (15%) or IM (7%) alone after 72 h (Fig. 5B) . Non-GRP78-reactive scFv-20 was used as a negative control.
Immunofluorescence with scFv-GRP78-H19 detected a weak signal of surface-located GRP78 in PC-3 cells (Fig. 6A) . Following treatment with IM (100 nM) for 76 h, both surface-located and intracellular GRP78 were increased significantly (Fig. 6B) . No specific cell surface or intracellular staining was observed using control antibody scFv-20 following exposure of cells to the same concentration of IM (Fig. 6C) .
To investigate the mechanism of scFv-GRP78-H19-mediated apoptosis, caspase 3/7 activity was measured following the treatment of PC-3 cells with IM, scFv-GRP78-H19 or a combination of both (Fig. 6D) . Treatment of PC-3 cells with IM (100 nM) or scFv-GRP78-H19 (83 nM) for 72 h produced a 1.4-fold and 2-fold increase in caspase-3/7 activity respectively, while the combination of both resulted in a 3-fold increase.
ScFv-GRP78-H19 inhibited etoposide drug resistance in colon and prostate cancer cells under glucose deprived condition
Glucose deprivation-mediated GRP78 increase has been shown previously to provide cytoprotection against etoposide-mediated apoptosis in colon cancer cell line HT-29 under either 2-Deoxyglucose (2DG) treatment or glucose-free medium treatment [17] . To determine whether scFv-GRP78-H19 antibody can attenuate GRP78-mediated drug resistance against etoposide, HT-29 colon cancer cells were treated with etoposide(10µg/ml) only, etoposide and 2DG(20mM), scFv-GRP78-H1 antibody(83nM) only, scFv-GRP78-H19 antibody plus etoposide and 2DG, heat-inactive scFv-GRP78-H1 antibody plus etoposide and 2DG (Fig.7A) . We found that after 48 h treatment, there were 7%+2 cells having apoptotic nuclei and nuclear DNA strand break, visualized using Hoechst DNA dye H33342 in etoposide treated samples (Fig.7A) . Such apoptotic cells disappeared after treating cells with 2DG and etoposide, which led GRP78 protein increase (Fig.8) . Although treating HT-29 cells with the scFv-GRP78-H19 antibody induced 8%+3 apoptotic cells, there were significant apoptotic cell death (22%) in the scFv-GRP78-H19 antibody plus etoposide and 2DG treatment group, indicating the antibody can attenuate etoposide drug resistance in colon cancer cells under glucose-deprivation (Fig.7A) . Importantly, the heat-inactive form of the antibody has no such effect (pre-treatment of the antibody at 100 0 C for 20 minutes) on the same condition. Similarly, human prostate cancer PC-3 cells were treated scFv-GRP78-H19 (83 nM) together with etoposide (10µg/ml) and 2DG (20mM), causing significant apoptotic cell death (31%) than treatment with scFv-GRP78-H19 (15%) or etoposide (8%) alone after 48 h treatment (Fig.  7B) . Again, the heat-inactive form of antibody had no effect on the same condition.
Western blotting was used to access GRP78 protein level in the above conditions in HT-29 colon cancer cell line (Fig.8) . We found that treating cells with 2DG alone (Fig.8, lane 3) and 2DG plus etoposide (Fig.8, lane 4) led GRP78 protein increase. However, GRP78 has significantly decreased with the ScFv-GRP78-H19 antibody treatment, indicating the antibody enhanced the etoposide cytotoxicity by decreasing GRP78 protein level (Fig.8, track 5) . 
Discussion
Therapeutic MAbs have enormous potential for the treatment of cancer. Since 1997, the first therapeutic antibody, rituximab (Rituxan; Genetich/Biogen Idec) was approved to treat Bcell non-Hodgkin"s lymphoma, there have been tremendous advance in this field and more than 17 therapeutic antibodies approved by FDA for cancer treatment [1, 2] . Technical advances on the antibody based therapy have also been rapidly developed. Progress in molecular biology and immunology has allowed the derivation of specific recognition domains from MAbs. Bacteriophage encoding a single Immunoglobulin variable (V) gene -domain antibody fragment on their surface was first developed in 1990 [18] . In recent years, phage display of nonimmune, human naï ve single-chain Fv (scFv) or Fab antibody repertoires has proven to be an important tool for generating highly specific antibody [1.2] . In fact, most of newly developed antibodies entering clinical trails are derived from phage display technology or transgenic mice that express human immunoglobulin genes [2] .
The advantage of the newly developed phage display libraries is that it contains the up to 10 8 diversified and individual recombinant scFv fragments, which fit for high-throughput screening [15] . Identification of tumor-specific cell surface antigens is the first and critical step toward the development of targeted therapeutics for cancer, many attempts have been used in this type of phage display technology to find the tumor specific antibodies [4] . In fact, Jakobsen et al., [19] recently described isolation of anti-GRP78 monoclonal scFv antibodies from a phage display library using live primary breast cancer cells. Some of them, such as Ab39 have been shown to be able to bind breast cancer surface. However, the success of direct cell selection using tumor cell has been limited. This is partly due to a high none specific binding of phage to cell surface and partly due to the high presentation of phage antibody binding to high presentation normal molecules, which present in both normal and tumor cells. The other bottle neck is subsequent proteomic work involved in identify the target antigen. In this study, we selected to use GRP78 recombinant protein as bait first for screening the phage library to eliminate the non specific binding present in the complex phage libraries, and then subjected the pooled positive phage to the cell surface GRP78 for selection. This crucial subtractive step was used to eliminate those positive GRP78 phage, which only binding to the intracellular proteins. After the cell surface selection, the positive phages were subjected to final selections using recombinant protein. These simple and alterative selections were enabling us to isolate cell surface-specific anti-GRP78 scFV antibody over 100 million different scFv fragments in the "naïve" or "single pot" phageantibody libraries.
We have demonstrated that the isolated anti-GRP78 cell surface targeting scFV was capable of targeting cell surface antigen and reducing endogenous GRP78 protein level. In addition, due to relative small size of the single-domain antibody and its ability to internalize, a surfacetargeting GRP78 scFv antibody could be internalize into the target cells and direct interact with cytosolic components mediating the apoptotic pathway. Our observation that antimembrane-bound GRP78 scFv dramatically increased the target cancer cell caspase-3/7 activity implicated that it could interfere with the GRP78-procaspase-7 inhibitory complex [13] , a key component that provides cancer cell apoptosis-resistance against several commonly used anti-cancer drugs, such as etoposide [20] .
Recently, Misra et al., [21] demonstrated that antibodies directed against the COOH-terminal domain of GRP78 up-regulated the tumor suppressor protein p53, while antibody directed against the NH(2)-terminal domain showed negligible effect on p53 expression. This study, together with our own antibody study, have highlighted the possibility that anti-GRP78 antibodies have the potential to be used therapeutically for the treatment of cancer.
The most dramatic observation of our study was that by combination the scFv-GRP78-H19 antibody and 2DG and topoisomerase inhibitors such as etoposide could dramatically increase colon and prostate tumor cell apoptosis. It is wellknown that in poorly vascularized solid tumors, where glucose deprivation and chronic anoxia are known to persist, GRP78 has been found as one of the major stress inducible proteins [12] . Indeed, GRP78 have been detected in majority of breast cancer samples [22] and in the late-stage malignant prostate cancer [23.24] and colon cancer [25] . From GRP78 transgenic experiment [26] , it has been shown GRP78 protein played a major role in tumor cell proliferation and angiogenesis. More importantly, partial reduction of GRP78 in mice substantially reduced tumor cell angiogenesis without detrimental effect on normal tissue vasculature. Therefore, GRP78 acts as an ideal biomarker for tumor cell proliferation and angiogenesis. The combination treatment of GRP78 antibody and other chemotherapeutic agents such as etoposide could hold a major advance in treatment of many solid tumors, in which epotoside currently has already used as a form of chemotherapy such as Ewing's sarcoma, lung cancer, testicular cancer, prostate cancer, colon cancer lymphoma, non-lymphocytic leukemia, and glioblastoma multiform [27] .
The work presented here has highlighted the possibility that anti-GRP78 antibodies have the potential to be used therapeutically for the treatment of cancer. In comparison with small interference RNA (siRNA) of GRP78 (27) , scFv anti-GRP78 does not need transfection reagent. It relative small size and easily penetration of tumor tissue make it more attractive as therapeutic reagent.
Finally, the subtraction antibody screening method described here has potential application for the isolation of MAbs targeting other surface-located proteins. Recently, by using biotinylation, many previously thought to be intracellular proteins such as GRP78, GRP75, HSP70, HSP60, HSP54, HSP27, and protein disulfide isomerase [10] , were found to be highly abundant on the cancer cell surface, therefore warranted to be explore using alternative subtraction screening described here to identify membrane-bound antibodies for future antibodymediated cancer therapy study.
